← All trials
NCT05650320
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2022
- Primary completion
- Dec 30, 2023
- Completion date
- Feb 28, 2024
- First posted
- Dec 14, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 240
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- OtsukaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.